#psychedelic medicine Tech News.
1 story in the last 7 days
The latest psychedelic medicine news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks psychedelic medicine across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
HealthForbes Innovationabout 13 hours ago
Eli Lilly's $3.8 Billion Psychedelic BetEli Lilly acquired AtaiBeckley for up to $3.8 billion, centered on the Phase 3 DMT-based nasal spray BPL-003 for treatment-resistant depression. The deal is the largest in the psychedelic-medicine sector. Johnson & Johnson's Spravato, annualizing close to $2 billion in sales, proved commercial viability for in-clinic psychedelic-adjacent therapies.
Summaries by ByteBrief